Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Zymeworks (NYSE: ZYME ) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (NASDAQ: JAZZ ). This agre...
Jazz Pharmaceuticals to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50 million upfront payment, a second payment of $325 million, at Jazz’s option, and further potential regulatory...
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody Canada NewsWire Jazz to obtain exclusive development and commercialization rights in key markets including the ...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its third quarter 2022 financial results after market close on November 8 th , 2022. Following the announcement, management...
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the completion of its previously announced intention to complete a series of transactions (the &...
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce that the Company’s securityholders have approved its plan to become a Delaware cor...
Wells Fargo analyst James Shin and the team assumed coverage on cancer-focused biotech Zymeworks Inc. ( NYSE: ZYME ) with an Overweight recommendation Tuesday, noting a range of catalysts the Canadian company expects to generate over the next several months. However, the fir...
The Redomicile is anticipated to provide greater opportunities to enhance long-term value for securityholders, simplify commercialization efforts and monetization opportunities for our product candidates, and provide greater comparability to our peers. Leading independent pr...
Summary Two new Breakout Stocks for Week 40 with better than 10% short-term upside potential and one Dow 30 pick. Average cumulative returns now up to +105.6% YTD. This week 2 picks beat 10% in less than a week with FUSN +12.2%, LRMR at +12.95% and VYGR +9.2% peak gains continuing...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences: Stifel 2022 Healthcare Conference . Zymeworks’ manageme...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...